You are here: Industry Insights > Market News > TriLink BioTechnologies to Move to New Facility

Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!

Note: You can unsubscribe from the alerts at any time.

Advertising

New Products

3-Bromo-4-fluorobenzaldehyde

5-Methyl-1,3,4-oxadiazol2(3H)-one

4-Amino-6-methyl-3 oxo2,3, 4,5-tetrahydro 1.2.4-triazine hydrochloride

4-Acetylamino-6-methyl -3-oxo-2,3,4,5-tetrahydro-1,2,4-triazine

3-Pyridinecarboxaldehyde

Ethyl 3 Fluorobenzoate

TriLink BioTechnologies to Move to New Facility

contractpharmaSeptember 13, 2018

Tag: facility , Maravai LifeSciences , TriLink BioTechnologies

Favorites

Maravai LifeSciences announced plans to relocate and expand its TriLink BioTechnologies operations with the signing of a lease on a new facility in the Sorrento Valley area of San Diego.

TriLink will consolidate its San Diego facilities into a new 95,000-square-foot space with an option to expand for future growth. The new facility will house the company’s current local staff of more than 150 and can accommodate growth to more than 350 R&D, commercial and manufacturing employees. The company’s current Good Manufacturing Practice (cGMP) production capabilities will also be relocated, validated and expanded.

TriLink will be the lead tenant in the 180,000-square-foot building, which is located at 10770 Wateridge Circle. The company will begin its move in the fall of 2019, with completion by the end of the year. Maravai LifeSciences corporate headquarters will also relocate to the new building.

"This new facility and related investments we are making in the business position us well for the continuing growth we foresee," said Brian Neel, chief operating officer for TriLink. "We can now further scale up our chemistry and biological operations in a state-of-the-art facility and meet the demand for our products in the growing fields of gene editing and DNA/RNA therapeutics and diagnostics. The new space will also enable us to create individual cGMP suites that can be tailored for customer campaigns."

-----------------------------------------------------------------------------
Editor's Note:

To apply for becoming a contributor of En-CPhI.cn,

welcome to send your CV and sample works to us,

Email: Julia.Zhang@ubmsinoexpo.com.

Previous:Bloom Science, Biose industrie Enter Mfg. Agreement

Next:Lilly streams £5m into virtual lab pact with UCL, Imperial

BioPharmaSpec Announces Three New Facilities in Freiburg, Bergamo and Vilnius

Biotech NewswireNovember 20, 2024

BioPharmaSpec, the leading global Contract Research Organization (CRO) for Discovery and Preclinical Characterization of Biopharmaceuticals, has officially announced three new European facilities.

Rona Therapeutics Presented Positive Phase 1 Results of RN0191, a Novel siRNA Therapy Targeting PCSK9, at the 2024 American Heart Association (AHA) Scientific Sessions

PR NEWSWIRENovember 20, 2024

AI in Pharmacovigilance: Predicting & Preventing Drug Risks

Nurah EkhlaqueNovember 19, 2024

TriLink BioTechnologies to Move to New Facility | Pharmasources.com

InnoCare Announces First Subject Dosed in the Phase III Registrational Trial of TYK2 Inhibitor ICP-332 for the Treatment of Atopic Dermatitis in China

PharmaSourcesNovember 15, 2024

InnoCare Announces First Subject Dosed in the Phase III Registrational Trial of TYK2 Inhibitor ICP-332 for the Treatment of Atopic Dermatitis in China

TriLink BioTechnologies to Move to New Facility

Related News

BioPharmaSpec Announces Three New Facilities in Freiburg, Bergamo and Vilnius

Rona Therapeutics Presented Positive Phase 1 Results of RN0191, a Novel siRNA Therapy Targeting PCSK9, at the 2024 American Heart Association (AHA) Scientific Sessions

AI in Pharmacovigilance: Predicting & Preventing Drug Risks

InnoCare Announces First Subject Dosed in the Phase III Registrational Trial of TYK2 Inhibitor ICP-332 for the Treatment of Atopic Dermatitis in China

You may like
More>>

TriLink BioTechnologies to Move to New Facility

Related News

BioPharmaSpec Announces Three New Facilities in Freiburg, Bergamo and Vilnius

Rona Therapeutics Presented Positive Phase 1 Results of RN0191, a Novel siRNA Therapy Targeting PCSK9, at the 2024 American Heart Association (AHA) Scientific Sessions

AI in Pharmacovigilance: Predicting & Preventing Drug Risks

InnoCare Announces First Subject Dosed in the Phase III Registrational Trial of TYK2 Inhibitor ICP-332 for the Treatment of Atopic Dermatitis in China

You may likeMore>>

You may like
More>>